Pfizer seeks full FDA approval of Paxlovid as questions about its benefits grow

A standard clearance could further broaden Paxlovid’s fast-rising use. But weaknesses are emerging too, among them unclear benefits in vaccinated people and a potential lack of potency against new variants.